Refine Search

Search Results -

Terms	Documents
melatonin same liposome	10

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L1

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Wednesday, March 16, 2005 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L1	melatonin same liposome	10	L1

END OF SEARCH HISTORY

First Hit Fwd Refs Previous Doc Next Doc Go to Doc#
Generate Collection Print

L1: Entry 3 of 10 File: USPT Nov 20, 2001

DOCUMENT-IDENTIFIER: US 6319517 B1
TITLE: Pharmaceutical preparation comprising lyophilized liposomes encapsulating an active principle which is highly insoluble in water, and the process for preparing the said preparation

Brief Summary Text (55):
Proceeding as described above, aqueous liposome compositions are obtained comprising about 8 mg/ml of melatonin, 3.8 mg/ml of lonidamine, 1 mg/ml of cyclosporin A and 4 mg/ml of bindarit against a water-solubility of 3.times.10.sup.-3 mg/ml (lonidamine), 1.times.10.sup.-1 mg/ml (bindarit) and, practically, the absolute insolubility of melatonin (G. S. Shida et al. "J. Pineal Res." 1994, 16, 198-201) and of cyclosporin A ["Insoluble in Water", a monograph of cyclosporin A in "Analytical Profiles of Drug Substances", 16, 163, (1987)].

Detailed Description Text (63):
Preparation III was lyophilized as described in Example 1 above, and the average size of the liposomes before and after lyophilization (Table 2/1), as well as the average size of the liposomes and the amount of melatonin in the fresh preparations and in those kept at 5.degree. C., were determined as described in the aforementioned example (Table 2/2).

Previous Doc Next Doc Go to Doc#

L1: Entry 5 of 10 File: USPT Apr 6, 1999

DOCUMENT-IDENTIFIER: US 5891465 A
TITLE: Delivery of biologically active material in a liposomal formulation for administration into the mouth

Detailed Description Text (34):
On the day of experimentation Baseline "0" melatonin levels were drawn. Two sprays of melatonin liposome spray formula was applied to sublingual area of the mouth. Saliva was allowed to accumulate for several minutes and then swallowed. Blood samples were drawn at 1/2 hour, 1 hour, 11/2 hours, 2 hours, 4 hours, 6 hours and 8 hours.

CLAIMS:

1. A liposomal composition suitable for the aerosol or spray delivery of melatonin to a subject, said composition comprising melatonin and optionally an additional supplement in phospholipid liposomes and a carrier wherein the liposomes have between about 20 nm and 10 microns in diameter and results in absorption into the blood stream, when administered, wherein the phospholipid liposome comprises one or more bilayer forming lipids, wherein said composition provides an increase in bioavailability of said supplement or drug of approximately 20 % or more when compared to an orally administered solid form, and wherein said composition comprises by weight percent, from about 0.25 to 20% lecithin, from about 0.025 to 2% cholesterol or zoosterol or phytosterol, from about 0.01 to 3% antioxidant, from about 0.05 to 0.4% melatonin, from about 0.1 to 20% glycerin, propylene glycol or butylene glycol, from about 0.1% to 10% ethanol, from about 0.015 to 4% anti microbial agent and from about 2 to 99.9% water.

First Hit Fwd Refs Previous Doc Next Doc Go to Doc#
Generate Collection Print

L1: Entry 2 of 10 File: USPT Jan 8, 2002

DOCUMENT-IDENTIFIER: US 6337087 B1
TITLE: Aqueous pharmaceutical composition comprising an active ingredient which is highly insoluble in water

Detailed Description Text (14):
quantity of melatonin trapped in the liposomes.

Detailed Description Paragraph Table (1):
Parameters Significance liposome size stability in the formulation time; measurement of the "fusion" of the vesicles; melatonin amount concentration of melatonin in the aqueous liposomal composition; stability in the formulation time;

Previous Doc Next Doc Go to Doc#

First Hit Previous Doc Next Doc Go to Doc#

End of Result Set

Generate Collection Print

L1: Entry 10 of 10 File: DWPI Nov 20, 1997

DERWENT-ACC-NO: 1998-008557
DERWENT-WEEK: 200045

TITLE: Liposomal formulation for administration as aerosol or liquid droplet spray - for drug or nutritional supplement administration either orally or nasally

INVENTOR: FISHER, D L; KELLER, B C ; KISS, S

PATENT-ASSIGNEE: BIOZONE LAB INC (BIOZN)

PRIORITY-DATA: 1996US-0645894 (May 14, 1996)

Search Selected Search ALL Clear

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9742938 A1	November 20, 1997	E	032	A61K009/127
JP 2000510841 W	August 22, 2000		028	A61K009/127
US 5891465 A	April 6, 1999		000	A61K009/127
EP 928189 A1	July 14, 1999	E	000	A61K009/127

DESIGNATED-STATES: CA JP YU AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
WO 9742938A1	April 21, 1997	1997WO-US06618	
JP2000510841W	April 21, 1997	1997JP-0540877	
JP2000510841W	April 21, 1997	1997WO-US06618	
JP2000510841W		WO 9742938	Based on
US 5891465A	May 14, 1996	1996US-0645894	
EP 928189A1	April 21, 1997	1997EP-0921295	
EP 928189A1	April 21, 1997	1997WO-US06618	
EP 928189A1		WO 9742938	Based on

INT-CL (IPC): A61 K 9/12; A61 K 9/127

ABSTRACTED-PUB-NO: US 5891465A
BASIC-ABSTRACT:

Composition for administering an agent comprises an aerosol or spray for oral or nasal administration comprising the agent in a lipid encapsulated form.

The agent can be selected from, e.g. Ginkgo biloba extract, Kava extract, Ginseng extract, Saw Palmetto extract, glucosamine sulphate, chromium picolinate, Milk thistle extract, Grape seed extract, Ma Huang extract, melatonin, Echinecia, Co-Q10 supplement, water soluble vitamins, fat soluble vitamins and combinations thereof. Alternatively, the agent may be a drug. The lipid vesicle or liposome, encapsulating the agent, comprises one or more lipids selected from lecithin, ceramides, phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine and cardiolipin. The liposomal preparation may contain different types of liposomes, e.g. small unilamellar vesicles, large unilamellar vesicles, multilamellar vesicles or oligolamellar vesicles.

USE - The composition is used for delivering an active agent orally or nasally. Active agents include nutritional supplements particularly herbs and plant extracts or drugs e.g. hormones, cardiovascular agents, antiarrthymics, calcium channel blocking agents, vasopressors, beta -adrenergic blocking agents, antihypertensives, CNS stimulants, analgesics, antiemetic/antivertigo agents, antianxiety agents, antidepressants, antipsychotics, sedative hypnotics, anticonvulsants, muscle relaxants, anti-Parkinson agents, antimicrobial agents, antiviral agents and antibiotics. The agent is absorbed sublingually, particularly under the tongue and between the cheek and the gum or can be administered nasally for local or systemic action.

ADVANTAGE - The formulations provide bioavailability improved from approx. 20-50% when compared to an orally administered solid form.

ABSTRACTED-PUB-NO: WO 9742938A
EQUIVALENT-ABSTRACTS:

Composition for administering an agent comprises an aerosol or spray for oral or nasal administration comprising the agent in a lipid encapsulated form.

The agent can be selected from, e.g. Ginkgo biloba extract, Kava extract, Ginseng extract, Saw Palmetto extract, glucosamine sulphate, chromium picolinate, Milk thistle extract, Grape seed extract, Ma Huang extract, melatonin, Echinecia, Co-Q10 supplement, water soluble vitamins, fat soluble vitamins and combinations thereof. Alternatively, the agent may be a drug. The lipid vesicle or liposome, encapsulating the agent, comprises one or more lipids selected from lecithin, ceramides, phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine and cardiolipin. The liposomal preparation may contain different types of liposomes, e.g. small unilamellar vesicles, large unilamellar vesicles, multilamellar vesicles or oligolamellar vesicles.

USE - The composition is used for delivering an active agent orally or nasally. Active agents include nutritional supplements particularly herbs and plant extracts or drugs e.g. hormones, cardiovascular agents, antiarrthymics, calcium channel blocking agents, vasopressors, beta -adrenergic blocking agents, antihypertensives, CNS stimulants, analgesics, antiemetic/antivertigo agents, antianxiety agents, antidepressants, antipsychotics, sedative hypnotics, anticonvulsants, muscle relaxants, anti-Parkinson agents, antimicrobial agents, antiviral agents and antibiotics. The agent is absorbed sublingually, particularly under the tongue and between the cheek and the gum or can be administered nasally for local or systemic action.

ADVANTAGE - The formulations provide bioavailability improved from approx. 20-50% when compared to an orally administered solid form.

CHOSEN-DRAWING: Dwg.0/0

DERWENT-CLASS: B05 B07
CPI-CODES: B12-M01A; B12-M11F;

Previous Doc Next Doc Go to Doc#

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 10 of 10 returned.

☐ 1. Document ID: US 6635274 B1

Using default format because multiple data bases are involved.

L1: Entry 1 of 10 File: USPT Oct 21, 2003

US-PAT-NO: 6635274
DOCUMENT-IDENTIFIER: US 6635274 B1

TITLE: Solution-based transdermal drug delivery system

DATE-ISSUED: October 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Masiz; John J.	Topsfield	MA		
Carter; Stephen G.	Andover	MA		

US-CL-CURRENT: 424/449; 424/447

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

☐ 2. Document ID: US 6337087 B1

L1: Entry 2 of 10 File: USPT Jan 8, 2002

US-PAT-NO: 6337087
DOCUMENT-IDENTIFIER: US 6337087 B1

TITLE: Aqueous pharmaceutical composition comprising an active ingredient which is highly insoluble in water

DATE-ISSUED: January 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cavallo; Giovanni	Ostia			IT
Marchitto; Leonardo	Cupra Marittima			IT

US-CL-CURRENT: 424/450

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

☐ 3. Document ID: US 6319517 B1

L1: Entry 3 of 10 File: USPT Nov 20, 2001

US-PAT-NO: 6319517
DOCUMENT-IDENTIFIER: US 6319517 B1

TITLE: Pharmaceutical preparation comprising lyophilized liposomes encapsulating an active principle which is highly insoluble in water, and the process for preparing the said preparation

DATE-ISSUED: November 20, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cavallo; Giovanni	Ostia			IT
Marchitto; Leonardo	Cupra Marittima			IT

US-CL-CURRENT: 424/450; 264/4.1, 264/4.3, 424/1.21, 424/417, 424/9.321, 424/9.51, 514/2, 514/21, 514/8

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

☐ 4. Document ID: US 6075045 A

L1: Entry 4 of 10 File: USPT Jun 13, 2000

US-PAT-NO: 6075045
DOCUMENT-IDENTIFIER: US 6075045 A

TITLE: Method of treating paralysis of the extremities caused by cerebral infarction

DATE-ISSUED: June 13, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Nishino; Hitoo	Nagoya			JP
Borlongan; Cesario V.	Silver Spring	MD		
Uneyama; Hisayuki	Kawasaki			JP

US-CL-CURRENT: 514/419

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

☐ 5. Document ID: US 5891465 A

L1: Entry 5 of 10 File: USPT Apr 6, 1999

US-PAT-NO: 5891465

DOCUMENT-IDENTIFIER: US 5891465 A

TITLE: Delivery of biologically active material in a liposomal formulation for administration into the mouth

DATE-ISSUED: April 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Keller; Brian C.	Antioch	CA		
Fisher; Daniel L.	Pleasant Hill	CA		
Kiss; Steven	Pittsburg	CA		

US-CL-CURRENT: 424/450; 424/43, 424/45, 424/727, 424/728, 424/734, 424/737, 424/766

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw De

---

☐ 6. Document ID: US 5716638 A

L1: Entry 6 of 10 File: USPT Feb 10, 1998

US-PAT-NO: 5716638
DOCUMENT-IDENTIFIER: US 5716638 A

TITLE: Composition for applying active substances to or through the skin

DATE-ISSUED: February 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Touitou; Elka	Jerusalem			IL

US-CL-CURRENT: 424/450; 264/4.1, 264/4.3, 424/401, 424/63

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw De

---

☐ 7. Document ID: US 20010051652 A1

L1: Entry 7 of 10 File: DWPI Dec 13, 2001

DERWENT-ACC-NO: 2002-146989
DERWENT-WEEK: 200219
COPYRIGHT 2005 DERWENT INFORMATION LTD
TITLE: Use of melatonin for the treatment of paralysis of the extremities caused by cerebral infarction

INVENTOR: BORLONGAN, C V; NISHINO, H ; UNEYAMA, H

PRIORITY-DATA: 1999US-0300456 (April 28, 1999), 2000US-0563902 (May 4, 2000), 2001US-0754312 (January 5, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20010051652 A1	December 13, 2001		006	A61K031/40

INT-CL (IPC): A61 K 31/40

☐ 8. Document ID: DE 69828394 E, WO 9836736 A1, ZA 9801352 A, AU 9864969 A, CZ 9902925 A3, EP 981332 A1, CN 1248163 A, SK 9901110 A3, HU 200001464 A2, IT 1289938 B, KR 2000075479 A, MX 9907684 A1, US 6319517 B1, JP 2001519776 W, AU 744115 B, SK 282931 B6, IL 131327 A, EP 981332 B1

L1: Entry 8 of 10 File: DWPI Feb 3, 2005

DERWENT-ACC-NO: 1998-467265
DERWENT-WEEK: 200510

TITLE: Lyophilised composition - comprises trehalose and lipid liposome(s) including water insoluble biologically active component

INVENTOR: CAVALLO, G; MARCHITTO, L

PRIORITY-DATA: 1997IT-MI00362 (February 20, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 69828394 E	February 3, 2005		000	A61K009/127
WO 9836736 A1	August 27, 1998	E	020	A61K009/127
ZA 9801352 A	October 28, 1998		020	A61K000/00
AU 9864969 A	September 9, 1998		000	A61K009/127
CZ 9902925 A3	January 12, 2000		000	A61K009/127
EP 981332 A1	March 1, 2000	E	000	A61K009/127
CN 1248163 A	March 22, 2000		000	A61K009/127
SK 9901110 A3	May 16, 2000		000	A61K009/127
HU 200001464 A2	October 30, 2000		000	A61K009/127
IT 1289938 B	October 19, 1998		000	A61K000/00
KR 2000075479 A	December 15, 2000		000	A61K009/127
MX 9907684 A1	June 1, 2000		000	A61K009/127
US 6319517 B1	November 20, 2001		000	A61K009/127
JP 2001519776 W	October 23, 2001		020	A61K009/127
AU 744115 B	February 14, 2002		000	A61K009/127
SK 282931 B6	January 9, 2003		000	A61K009/127
IL 131327 A	July 25, 2004		000	A61K009/127
EP 981332 B1	December 29, 2004	E	000	A61K009/127

282931 B6 , IL 131327 A INT-CL (IPC): A61 K 0/00; A61 K 9/127; A61 K 9/19; A61 K 31/4045; A61 K 31/41; A61 K 31/416; A61 K 38/00; A61 K 38/13; A61 K 47/26; B01 F 0/00; B01 J 0/00

☐ 9. Document ID: MX 217521 B, WO 9836735 A1, ZA 9801354 A, AU 9863987 A, CZ 9902926 A3, EP 973505 A1, SK 9901111 A3, CN 1255057 A, HU 200000910 A2, IT 1289939 B, KR 2000075480 A, MX 9907683 A1, AU 740619 B, JP 2001519775 W, US 6337087 B1, SK 282905 B6, EP 973505 B1, DE 69821001 E, ES 2213894 T3

L1: Entry 9 of 10 File: DWPI Nov 12, 2003

DERWENT-ACC-NO: 1998-467264
DERWENT-WEEK: 200468

TITLE: Aqueous pharmaceutical compositions - comprise active ingredient highly insoluble in water, e.g. lonidamine, melatonin, cyclosporin A or bindarit, dispersed in liposomes

INVENTOR: CAVALLO, G; MARCHITTO, L

PRIORITY-DATA: 1997IT-MI00363 (February 20, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
MX 217521 B	November 12, 2003		000	A61K009/127
WO 9836735 A1	August 27, 1998	E	020	A61K009/127
ZA 9801354 A	October 28, 1998		017	A61K000/00
AU 9863987 A	September 9, 1998		000	A61K009/127
CZ 9902926 A3	January 12, 2000		000	A61K009/127
EP 973505 A1	January 26, 2000	E	000	A61K009/127
SK 9901111 A3	June 12, 2000		000	A61K009/127
CN 1255057 A	May 31, 2000		000	A61K009/127
HU 200000910 A2	October 30, 2000		000	A61K009/127
IT 1289939 B	October 19, 1998		000	A61K000/00
KR 2000075480 A	December 15, 2000		000	A61K009/127
MX 9907683 A1	June 1, 2000		000	A61K009/127
AU 740619 B	November 8, 2001		000	A61K009/127
JP 2001519775 W	October 23, 2001		028	A61K031/415
US 6337087 B1	January 8, 2002		000	A61K009/127
SK 282905 B6	January 9, 2003		000	A61K009/127
EP 973505 B1	January 7, 2004	E	000	A61K009/127
DE 69821001 E	February 12, 2004		000	A61K009/127
ES 2213894 T3	September 1, 2004		000	A61K009/127

B6 , EP 973505 B1 INT-CL (IPC): A61 K 0/00; A61 K 9/127; A61 K 31/192; A61 K 31/415; A61 K 31/416; A61 K 47/10; A61 K 47/12; A61 K 47/14; A61 K 47/24; A61 K 47/26; A61 P 15/08

☐ 10. Document ID: WO 9742938 A1, JP 2000510841 W, US 5891465 A, EP 928189 A1

L1: Entry 10 of 10 File: DWPI Nov 20, 1997

DERWENT-ACC-NO: 1998-008557
DERWENT-WEEK: 200045

TITLE: Liposomal formulation for administration as aerosol or liquid droplet spray - for drug or nutritional supplement administration either orally or nasally

INVENTOR: FISHER, D L; KELLER, B C ; KISS, S

PRIORITY-DATA: 1996US-0645894 (May 14, 1996)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9742938 A1	November 20, 1997	E	032	A61K009/127
JP 2000510841 W	August 22, 2000		028	A61K009/127
US 5891465 A	April 6, 1999		000	A61K009/127
EP 928189 A1	July 14, 1999	E	000	A61K009/127

INT-CL (IPC): A61 K 9/12; A61 K 9/127

Terms	Documents
melatonin same liposome	10